Shrewd M&A activity and R&D spending growth could help fuel future growth as the company goes on the offensive. Bausch Health Companies Inc. (BHC) plans to finally return to revenue growth in 2019 as the bloodshed looks to be coming to an end for the company even as it works to slowly resolve its legacy massive debt issues. With smart M&A decisions backed by a growing R&D budget, fueling future growth is becoming more of a concern for the company as growing revenues and a declining debt load could eventually result in a full rerating of the stock, albeit maybe still years in the future. Bausch’s core eye care business continues its solid performance with slow growth on over 50% of the company’s revenue streams while the company’s “Significant Seven” new product launches will be one of the keys to sustained revenue growth over the next 4 years. Revenues are expected to double for the seven in 2019 to ~$300M, with the goal of peak revenue streams of over $1B by the end of 2022. Bausch’s Salix division is the other key catalyst to creating greater future growth for the company. Bausch bought Salix back in 2015 in an almost $15B de...